1. Home
  2. REGCP vs GNLX Comparison

REGCP vs GNLX Comparison

Compare REGCP & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regency Centers Corporation

REGCP

Regency Centers Corporation

N/A

Current Price

$23.23

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo Genelux Corporation

GNLX

Genelux Corporation

HOLD

Current Price

$2.88

Market Cap

123.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGCP
GNLX
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
123.1M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
REGCP
GNLX
Price
$23.23
$2.88
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
3.3K
334.6K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
9.47
EPS
0.46
N/A
Revenue
$1,553,524,000.00
$8,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$50.98
N/A
Revenue Growth
6.85
N/A
52 Week Low
$22.35
$2.29
52 Week High
$24.74
$8.54

Technical Indicators

Market Signals
Indicator
REGCP
GNLX
Relative Strength Index (RSI) 50.74 55.44
Support Level $23.02 $2.68
Resistance Level $23.58 $2.98
Average True Range (ATR) 0.19 0.17
MACD 0.03 0.02
Stochastic Oscillator 43.21 80.49

Price Performance

Historical Comparison
REGCP
GNLX

About REGCP Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: